• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 19.87
  • VXN 23.66
  • VXO 22.89
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
     
NVAX (Novavax Inc)
Last Trade 6.235 Date 8/24/2019
Change % -5.96 % Price Change -0.40
Open 6.53 52 Week High 51.6
High 6.6495 52 Week Low 4.01
Low 6.05 Type stock
Volume 633239 Avg Volume 873877
Prev Close 6.63 Stock Exchange NASDAQ
Company Profile

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform technology. Its vaccine product candidates target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; Respiratory Syncytial Virus; and Varicella Zoster Virus that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza and H1N1 pandemic vaccine candidates, Cadila?s biogeneric products, and other diagnostic products for the territory of India. It also has a co-marketing agreement with GE Healthcare for a pandemic influenza vaccine solution. The company was founded in 1987 and is headquartered in Rockville, Maryland.